Zimmermann, P., Finn, A., & Curtis, N. (2018). Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: time for an urgent scientific response. *Medical Journal of Australia*, 209(3), [142]. <https://doi.org/10.5694/mja18.00502>

Peer reviewed version

Link to published version (if available):
[10.5694/mja18.00502](https://doi.org/10.5694/mja18.00502)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via MJA at <https://www.mja.com.au/journal/2018/209/3/tackling-worsening-epidemic-buruli-ulcer-australia-information-void-time-urgent> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

The worsening Buruli ulcer epidemic – a role for BCG vaccination?

Petra Zimmermann^{1,2,3,4}, MD, Adam Finn^{5,6,7}, FRCPCH, PhD, Nigel Curtis^{1,2,3}, FRCPCH, PhD

Affiliations:

¹ Department of Paediatrics, The University of Melbourne, Parkville, Australia

² Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Parkville, Australia

³ Infectious Diseases & Microbiology Research Group, Murdoch Children's Research Institute, Parkville, Australia

⁴ Infectious Diseases Unit, University of Basel Children's Hospital, Basel, Switzerland

⁵ School of Population Health Sciences and School of Cellular & Molecular Medicine, University of Bristol, Bristol, UK

⁶ Bristol Children's Vaccine Centre, Bristol, UK

⁷ University Hospitals Bristol NHS Foundation Trust, Bristol, UK

Address correspondence to: Dr Petra Zimmermann, Department of Paediatrics, The University of Melbourne, Royal Children's Hospital Melbourne, 50 Flemington Road, Parkville, 3052, Australia, petra.zimmermann@mcri.edu.au, +61 3 9345 5522

Alternate corresponding author: Prof Nigel Curtis, Department of Paediatrics, The University of Melbourne, Royal Children's Hospital Melbourne, 50 Flemington Road, Parkville, 3052, Australia, nigel.curtis@rch.org.au, +61 3 9345 6366

A recent article by O'Brien et al. highlights the worsening epidemic of Buruli ulcer in Australia. The steep rise in both the incidence and severity of the disease is associated with estimated health-care costs of over \$2.5 million per year in Victoria.¹

The increase in Buruli ulcer cases in Australia parallels the increase in non-tuberculous mycobacterial (NTM) infections, especially lymphadenitis and Buruli ulcer, reported worldwide. Although this rise might be partly attributable to improved awareness and diagnostic methods, it might also be related to the discontinuation of universal Bacillus Calmette-Guérin (BCG) vaccination in settings where the rate of tuberculosis has declined. Routine vaccination with BCG through the school program was discontinued in Victoria in the mid 1980s.

The live-attenuated strain of *M. bovis* contained in BCG vaccine shares epitopes with NTM, which makes cross-protection plausible. Our recently published meta-analysis indicates that BCG vaccination has a protective effect against NTM.² In particular, two randomised trials provide strong evidence for protection against *M. ulcerans*.^{3,4} However, protection might only be short lived, as the highest protection was observed in the first year after vaccination. Nevertheless, studies also report that compared with BCG-naïve individuals, those who are BCG-vaccinated have smaller skin lesions⁴, a shorter duration to healing⁵ and protection against severe forms of Buruli ulcer with multiple skin lesions.⁶

Buruli ulcer is a serious condition, which, despite prolonged antibiotic treatment and surgical intervention, can lead to complications such as osteomyelitis and other crippling sequelae. In light of the worsening epidemic, the protective effect of BCG vaccination should not be overlooked.

References

1. O'Brien DP, Athan E, Blasdel K, De Barro P. Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: time for an urgent scientific response. *The Medical journal of Australia* 2018;208:287-9.
2. Zimmermann P, Finn A, Curtis N. Does BCG Vaccination Protect Against Non-Tuberculous Mycobacterial Infection? A Systematic Review and Meta-Analysis. *The Journal of infectious diseases* 2018.
3. Bradley DJ, Hutt MSR, Kinyabwire JWM, et al. BCG vaccination against mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda. *Lancet* 1969;1:111-5.
4. Smith PG, Revill WD, Lukwago E, Rykushin YP. The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1976;70:449-57.
5. Amofah GK, Sagoe-Moses C, Adjei-Acquah C, Frimpong EH. Epidemiology of Buruli ulcer in Amansie West district, Ghana. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 1993;87:644-5.
6. Noeske J, Kuaban C, Rondini S, et al. Buruli ulcer disease in Cameroon rediscovered. *Am J Trop Med Hyg* 2004;70:520-6.